Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News UNITY Biotechnology Inc UBX

Healthcare Biotechnology
UNITY Biotechnology, Inc. is a biotechnology company engaged in researching and developing therapeutics to slow, halt or reverse diseases of aging. The Company is focused on creating medicines to selectively eliminate or modulate senescent cells and thereby provide transformative benefit in age-related ophthalmologic and neurologic diseases. It is targeting specific biological mechanisms... see more

Recent & Breaking News (NDAQ:UBX)

UNITY Biotechnology Announces Publication in NEJM Evidence Highlighting the Potential of Senolytic Therapeutics to Provide Long-Term Improvements in Vision in DME

GlobeNewswire 3 days ago

UNITY Biotechnology, Inc. Reports First Quarter 2025 Financial Results and Business Updates

GlobeNewswire 3 days ago

UNITY Biotechnology Announces Topline Results from the ASPIRE Phase 2b Study in Diabetic Macular Edema

GlobeNewswire March 24, 2025

UNITY Biotechnology to Host Virtual Investor Event to Discuss 24- and 36-Week Data from the Phase 2b ASPIRE Study of UBX1325 in Patients with Diabetic Macular Edema (DME) on March 24, 2025

GlobeNewswire March 23, 2025

UNITY Biotechnology Appoints Industry Leader and Ophthalmology Expert Yehia Hashad, M.D., to the Board of Directors

GlobeNewswire March 10, 2025

UNITY Biotechnology, Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Business Updates

GlobeNewswire March 7, 2025

UNITY Biotechnology Reports Granting of New Employment Inducement Award

GlobeNewswire January 7, 2025

UNITY Biotechnology Announces Appointment of Federico Grossi, M.D., Ph.D., as Chief Medical Officer

GlobeNewswire January 6, 2025

UNITY Biotechnology, Inc. Reports Third Quarter 2024 Financial Results and Business Updates

GlobeNewswire November 4, 2024

UNITY Biotechnology to Host In-Person Ophthalmology Day in New York on Tuesday, October 15, 2024

GlobeNewswire September 24, 2024

UNITY Biotechnology to Participate in Upcoming Investor Conferences

GlobeNewswire August 12, 2024

UNITY Biotechnology, Inc. Reports Second Quarter 2024 Financial Results and Business Updates

GlobeNewswire August 6, 2024

UNITY Biotechnology Reports Granting of New Employment Inducement Award

GlobeNewswire July 24, 2024

UNITY Biotechnology Announces Appointment of Alicia Tozier as Chief Strategy Officer

GlobeNewswire July 22, 2024

UNITY Biotechnology, Inc. Reports First Quarter 2024 Financial Results and Business Updates

GlobeNewswire May 14, 2024

UNITY Biotechnology Announces Upcoming Presentations at the ARVO 2024 Annual Meeting

GlobeNewswire April 25, 2024

UNITY Biotechnology Announces Extension of Phase 2b ASPIRE Clinical Study Evaluating UBX1325 in DME

GlobeNewswire April 23, 2024

UNITY Biotechnology, Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates

GlobeNewswire April 15, 2024

New Publication in Nature Medicine Supports Therapeutic Potential of Senolytics to Provide Long-lasting, Disease-modifying Intervention in Vision Loss

GlobeNewswire February 6, 2024

UNITY Biotechnology Doses First Patients in Phase 2 ASPIRE Study of UBX1325 in DME

GlobeNewswire December 12, 2023